Adjuvant Hormone Therapy
{"Image DocumentName": "Adjuvant Hormone Therapy", "Image ImageDescription": "EPC studies. 150 mg Bicalutamide. 3 randomised studies through the world. Significant PSA PFS if 150 mg Bicalutamide added after RRP for lacally advanced or high risk CaP. No difference with localised CaP. Survival is not altered. Risk Group. No. HR (95% CI) Locally advanced ( ) N ( ) GS ( ) PSA>10ng/ml ( )", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}